Recurrent ovarian cancer patients with 3-6 month treatment-free interval or 1-2 prior chemotherapy regimens might get benefit from tumor chemosensitivity assay directed chemotherapy

Li, Ning

435
Recurrent ovarian cancer patients with 3-6 month treatment-free interval or 1-2 prior chemotherapy regimens might get benefit from tumor chemosensitivity assay directed chemotherapy

Sunday, March 29, 2015: 7:00 AM

Salon C-D (Hilton Chicago)

N. Li¹, Y. T. Gao², R. Zhang², X. G. Li², Y. C. Sun², N. Li², B. Li², W. Zhang³ and L. Y. Wu⁴
¹Cancer Hostpital, Chinese Academy of Medical Sciences, Beijing, China, ²Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China, ³Cancer Hospital (Institute), Chinese Academy of Medical Sciences, Beijing, China, ⁴Cancer Hospital, Chinese Academy of Medical Sciences,, Beijing, China

2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Navigation

435
Recurrent ovarian cancer patients with 3-6 month treatment-free interval or 1-2 prior chemotherapy regimens might get benefit from tumor chemosensitivity assay directed chemotherapy

435 Recurrent ovarian cancer patients with 3-6 month treatment-free interval or 1-2 prior chemotherapy regimens might get benefit from tumor chemosensitivity assay directed chemotherapy

435
Recurrent ovarian cancer patients with 3-6 month treatment-free interval or 1-2 prior chemotherapy regimens might get benefit from tumor chemosensitivity assay directed chemotherapy